Elotuzumab for untreated multiple myeloma [ID966]

  • Discontinued
  • GID-TA10134
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations. Further information regarding the scheduling of this appraisal will be available in due course.